www.fdanews.com/articles/121977-xoma-expands-development-strategy-for-xoma-052
Xoma Expands Development Strategy for Xoma 052
November 6, 2009
XOMA Ltd. announced the expansion of its development strategy for its XOMA 052 antibody to interleukin-1 beta to include effects on cholesterol lowering,
reducing plaque deposits and damage to heart muscle and resulting long-term effects that can lead to heart attack, stroke and congestive heart failure.
CNNMoney
CNNMoney